Wenqian Xu
Shenyang Pharmaceutical University
ORCID: 0000-0003-4962-3295Also affiliated with Fujian Medical University, Beijing Technology and Business University, Hong Kong University of Science and Technology, Hunan Provincial Center for Disease Control and Prevention, Fujian Provincial Cancer Hospital
Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia”.
Lijun Peng, Wenqian Xu, Yuebo Zhou, Ziyan Zhu, Yushan Kong +5 more
Wenqian Xu, Shengyu Wang, Zhu Yu, Yue Feng, Da Li +2 more
Jin Wang, Sophie Rousseaux, Minjia Tan, Lulu Pan, Lijun Peng +19 more